JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation

• References

• 1 Menon KVN, Shah V, Kamath PS. The Budd-Chiari Syndrome. N Engl J Med 2004; 350: 578-585.
• 2 Denninger MH, Chaït Y, Casadevall N. et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
• 3 Janssen HLA, Meinardi JR, Vleggaar FP. et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364-2368.
• 4 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 2005; 365: 1054-1061.
• 5 Kralovics R, Passamonti F, Buser AS. et al. A gainof- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
• 6 Vardiman JW, Harris NL, Brunnung RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
• 7 Patel RK, Lea NC, Heneghan MA. et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038.
• 8 Deltenre P, Denninger MH, Hillaire S. et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48: 264-268.
• 9 Mahmoud AEA, Elias E, Beauchamp N. et al. Prevalence of factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
• 10 Souto JC, Coll I, Llobet D. et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-369.
• 11 Vayá A, Mira Y, Mateo J. et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-457.
• 12 Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214-4222.
• 13 Primignani M, Barosi G, Bergamaschi G. et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
• 14 Campbell PJ, Scott LM, Buck G. et al. Definition of subtipes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
• 15 Colaizzo D, Amitrano L, Iannaccone L. et al. Gain of function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet. 2007 prepub online.
• 16 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
• 17 Murad SD, Valla DC, de Groen PC. et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006; 101: 83-90.
• 18 18 Baba-Ahmed M, Le Gal G, Couturaud F. et al. High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis. Thromb Haemost 2007; 97: 171-175.